GSA Capital Partners LLP Invests $1.56 Million in Capricor Therapeutics, Inc. $CAPR

GSA Capital Partners LLP bought a new position in Capricor Therapeutics, Inc. (NASDAQ:CAPR) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 215,675 shares of the biotechnology company’s stock, valued at approximately $1,555,000.

Other large investors have also recently modified their holdings of the company. Envestnet Asset Management Inc. bought a new position in Capricor Therapeutics during the 3rd quarter worth $99,000. AlphaQuest LLC lifted its position in shares of Capricor Therapeutics by 396.2% during the 3rd quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 23,974 shares during the period. Parkside Financial Bank & Trust acquired a new position in shares of Capricor Therapeutics during the third quarter valued at about $36,000. HBK Sorce Advisory LLC boosted its holdings in Capricor Therapeutics by 33.7% in the third quarter. HBK Sorce Advisory LLC now owns 170,577 shares of the biotechnology company’s stock worth $1,141,000 after acquiring an additional 42,951 shares in the last quarter. Finally, Farther Finance Advisors LLC bought a new position in shares of Capricor Therapeutics in the 3rd quarter worth $28,000. Institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Trading Up 2.6%

Capricor Therapeutics stock opened at $23.03 on Wednesday. Capricor Therapeutics, Inc. has a 12 month low of $4.30 and a 12 month high of $40.37. The business’s 50 day simple moving average is $25.49 and its 200 day simple moving average is $13.98. The company has a market cap of $1.05 billion, a price-to-earnings ratio of -12.79 and a beta of 0.38.

Analysts Set New Price Targets

CAPR has been the topic of several research reports. Maxim Group upped their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, January 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Capricor Therapeutics in a research note on Wednesday, January 14th. HC Wainwright increased their price objective on Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, December 3rd. Finally, Piper Sandler restated an “overweight” rating and set a $45.00 price objective (up from $20.00) on shares of Capricor Therapeutics in a research note on Wednesday, December 10th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.82.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.